Haemato-Oncology Network Site Specific Group Minutes

Haemato-Oncology Network Site Specific Group Minutes Thursday 15th October 2015 Arundel Arms Hotel, Lifton PL16 0DE

This meeting was sponsored by Alexion, Amgen, Gilead, Pfizer, Janssen and Roche. Roche Products Limited has had no control over the educational content.

Attendees: Patrick Medd, PHT (Chair) Suzanne Greep, PHT Kerry McKay, PHT Rebecca Hick, PHT Susan Gilbert, PHT Sophie Kendall, PHT Adam Forbes, RCHT Linzi Retallick-Schmid, RCHT Deborah Turner, SDHT Libby Hardy, SWSCN Clare Fox, RDE Wendy Cook, PCRN Liz Boylan, PCN Mel Chandler, PCN

ACTION 1. Welcome and Apologies Patrick Medd chaired the meeting, he welcomed the group and apologies were accepted. 2. Minutes/Actions of Meeting held 14TH May 2015 2.1 The minutes of the last meeting were reviewed and accepted by the meeting. Action from last meeting: Catchment Population - the RDE and ND meeting the 500,000 requirement. The number 2.2 shown for RCHT is 534,000 for the whole of Cornwall which is slightly high. Need to ascertain the official number for RCHT. Action: AF to clarify the number on the table. User Representation - complete as it was agreed we only need one i.e. we do not require AF 2.3 one from each MDT. Pathology Leads have been confirmed as:- 2.4 Oncology – Chris Hamilton, RDE Radiology – Richard Riordan, PHT Pathology – Mark Smith,PHT Videoconferencing - on hold. Remove item. 2.5 ARIA Pro-Forma - is completed at MDT. Remove item. 2.6 Innovation Funding – Dr Turner said Celgene not interested. Remove item. 2.7 3. Terms of Reference 3.1 Approved by members present.

4. Constitution 4.1 Approved by members present. 4.2 It was noted that Loretta Ngu and Clare Fox were the new Joint MDT leads for RDE & ND. Action: LB to update Constitution LB 5. Clinical Guidelines 5.1 The group agreed to sign off the Clinical Haematological Malignancy Guidelines 2015 that

Haemato-oncology NSSG Minutes 15.10.15 draft v0.1 had been distributed with agenda as the Peninsula Network Clinical Guidelines. There will be a 6-monthly review by the following members for the next meeting.

Lymphoma – Deborah Turner

Myeloma – Adam Forbes

Chronic Lymphocytic Leukaemia – Jason Coppell Chronic Myeloid Leukaemia – Patrick Medd Acute Myeloid Leukaemia – Patrick Medd DT/AF/JC/PM Acute Lymphoblastic Leukaemia – Patrick Medd Myodysplasia – Patrick Medd Myeloproliferative Disorders – Patrick Medd Action: DT/AF/JC/PM to send LB any updates to Clinical Guidelines prior to next meeting

6. Patient Pathways 6.1 A sample Southwest 2WW Referral form has been circulated by Jonathan Miller, South West Cancer Network Manager. LB has been asked by Sian Dennison, PHT Cancer Services Manager, to present the current PHT 2WW Referral Form which she had updated to meet the latest referral guidelines. It was agreed we should look at a single network proforma for haematology Action: Everyone to send their forms to LB and she will co-ordinate review. ALL 7. Annual Report/Work Programme 7.1 The Annual Report and Work Programme were agreed. Action: PM agreed to arrange a separate meeting to discuss SIHMDS with the Patrick Roberts, Jason Coppell, Wayne Thomas, Bryson Pottinger, Mark Smith, Nigel Oakes and Jo Farrugia. Action: PM to provide feedback for next annual report. PM 8. Patient Representative 8.1 PM welcomed Sophie Kendall to her first NSSG meeting as patient representative and thanked her for her involvement. She said the treatment she had received was “world class”. 8.2 WC said that patient representation and their input on clinical trials was needed as they can give a “walk through” of their trial and say what they would like to see from a patient’s point of view. 9. Audit 9.1 DT has Plymouth’s figures but is waiting for Truro’s. Conversion rates vary. The Peninsula Cancer Network’s 2WW Audit form is attached to the back of these minutes. Action: DT to look at new figures and complete audit report.

DT 10. Research / Clinical Trials 10.1 DT had recently attended the Lymphoma Strategy SSG Group in London. There appears to be many holes in the research portfolio with industry holding trials in other countries but not the UK. We will probably need to do more commercial studies. All network leads did not know what their roles were. Getting varying information. DT 10.2 said she gets information quicker through the Trust than through the Research Network as Haematology Subspecialty Lead. WC said she would copy in the Sub Speciality Leads when she sends out research in the future. WC discussed financial penalties that will be applied if trusts to not meet the recruitment targets they have set when commencing a trial.

Haemato-oncology NSSG Minutes 15.10.15 draft v0.1 10.3 Action: WC to see if studies with very low targets could be excluded. WC leaves her post on 27th November and will be replaced by Julie Cunningham. WC 10.4

11. Living With & Beyond Cancer 11.1 Every trust has a Project Manager leading on this. DT is doing a health and wellbeing event next week. Action: LB to invite Wendi Abraham, Macmillan Patient Pathway Redesign Project Manager, to attend next meeting LB Action: CNS update from each trust for next meeting CNS 12. Any Other Business 12.1 Peer Review – Some issues raised included: Lack of Integrated Reports. Attendance of Histopathologists/Radiologists/Oncologists at MDTs 13. Date of Next Meetings 13.1 Thursday 28th April 2016 at the Arundel Arms, Lifton prior to the Blood Club meeting Thursday 20th October 2016 at the Arundel Arms, Lifton prior to the Blood Club meeting 13.2

Haemato-oncology NSSG Minutes 15.10.15 draft v0.1